RT Conference Proceedings
T1 First-line nivolumab (NIVO) plus ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA
A1 Reck, M.
A1 Ciuleanu, T-E.
A1 Cobo, M.
A1 Schenker, M.
A1 Zurawski, B.
A1 Menezes, J.
A1 Richardet, E.
A1 Bennouna, J.
A1 Cheng, Y.
A1 Paz-Ares, L.
A1 Lu, S.
A1 John, T.
A1 Padilla, B.
A1 Sun, X.
A1 Moisei, A.
A1 Yan, J.
A1 Yuan, Y.
A1 Blum, S. I.
A1 Carbone, D. P.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/24352
UL https://hdl.handle.net/10668/24352
LA en
DS RISalud
RD Apr 6, 2025